0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Shiga toxin associated hemolytic uremic syndrome.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Shiga toxin associated hemolytic uremic syndrome (Stx HUS), a thrombotic microangiopathy, is the most common cause of pediatric acute kidney injury but has no direct treatment. A better understanding of disease pathogenesis may help identify new therapeutic targets. For this reason, the role of complement is being actively studied while eculizumab, the C5 monoclonal antibody, is being used to treat Stx HUS but with conflicting results. A randomized controlled trial would help properly evaluate its use in Stx HUS while more research is required to fully evaluate the role complement plays in the disease pathogenesis.

          Related collections

          Author and article information

          Journal
          Hematol. Oncol. Clin. North Am.
          Hematology/oncology clinics of North America
          Elsevier BV
          1558-1977
          0889-8588
          Jun 2015
          : 29
          : 3
          Affiliations
          [1 ] Department of Molecular and Cell Biology, The Scripps Research Institute, MB 216, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA; Academic Renal Unit, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK. Electronic address: lskeir@doctors.org.uk.
          Article
          S0889-8588(15)00008-8
          10.1016/j.hoc.2015.01.007
          26043390

          Comments

          Comment on this article

          Similar content 662

          Cited by 6